Chemistry:Pivagabine
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
4-(2,2-Dimethylpropanamido)butanoic acid | |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
| EC Number |
|
| KEGG | |
| MeSH | N-trimethylacetyl-4-aminobutyric+acid |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C9H17NO3 | |
| Molar mass | 187.239 g·mol−1 |
| Pharmacology | |
| 1=ATC code }} | N06AX15 (WHO) |
| Oral | |
| Pharmacokinetics: | |
| 6.4 hours | |
| Legal status |
|
| Related compounds | |
Related alkanoic acids
|
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Pivagabine (INN; brand name Tonerg), also known as N-pivaloyl-γ-aminobutyric acid or N-pivaloyl-GABA, is an antidepressant and anxiolytic drug which was introduced in Italy in 1997 for the treatment of depressive and maladaptive syndromes. But it was discontinued in Italy (according to Martindale). Originally believed to function as a prodrug to GABA,[1] pivagabine is now believed to act somehow via modulation of corticotropin-releasing factor (CRF).[2][3][4][5][6]
See also
References
- ↑ "Pharmacokinetics and in vitro effects of a 4-aminobutyric acid derivative with anticonvulsant action". Pharmacology 27 (4): 237–40. 1983. doi:10.1159/000137876. PMID 6634934.
- ↑ "Effects of pivagabine on psychophysical performance and behavioural response in experimental models of stress". Arzneimittel-Forschung 47 (11A): 1310–4. November 1997. PMID 9450154.
- ↑ "Pivagabine: a novel psychoactive drug". Arzneimittelforschung 47 (11A): 1306–9. November 1997. PMID 9450153.
- ↑ "Pivagabine effects on neuroendocrine responses to experimentally-induced psychological stress in humans". Behavioural Brain Research 122 (1): 93–101. July 2001. doi:10.1016/S0166-4328(01)00177-2. PMID 11287080.
- ↑ "Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain". Psychoneuroendocrinology 24 (3): 269–84. April 1999. doi:10.1016/S0306-4530(98)00049-3. PMID 10101733.
- ↑ George I. Papakostas; Maurizio Fava (2010). Pharmacotherapy for Depression and Treatment-resistant Depression. World Scientific. pp. 370–. ISBN 978-981-4287-59-3. https://books.google.com/books?id=zigp-66vq0MC&pg=PA370.
 |  |
